[Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
Vinagre
Irene
I
Rigla
Mercedes
M
Torras
Xavier
X
Enríquez
Jaime
J
Corcoy
Rosa
R
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000139:chemically induced*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
D000998:Antiviral Agents; D001323:Autoantibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D005968:Glutamate Decarboxylase; C401141:glutamate decarboxylase 2; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a